Sponsors (57)
The bill strengthens 340B protections to lower drug acquisition costs for FQHCs and potentially reduce costs for low‑income patients, but risks manufacturer pushback that could limit supply or shift costs onto other purchasers and imposes short‑term enforcement burdens.
Federally Qualified Health Centers (FQHCs) will pay no more than the 340B ceiling price at purchase, lowering their immediate drug acquisition costs.
Patients served by FQHCs — often low‑income and uninsured — may face lower out‑of‑pocket or clinic service costs if centers retain savings from lower drug prices.
Hospitals and clinics will have clearer protections because the bill limits manufacturer contract terms that try to circumvent 340B, preserving statutory program benefits.
Hospitals and low‑income patients could face reduced drug availability if manufacturers restrict or refuse discounted sales to FQHCs in response.
Taxpayers and middle‑class families could see higher drug costs if manufacturers raise list prices or alter contracting practices to offset lost pricing flexibility.
Hospitals, clinics, and state agencies will face immediate enforcement and compliance duties, creating administrative burdens and transitional costs.
Based on analysis of 2 sections of legislative text.
Bars agreements that let FQHCs be charged above the 340B ceiling price at purchase and forbids pay-more-now/recoup-later arrangements.
Prohibits the HHS Secretary from entering into agreements with drug manufacturers that allow Federally Qualified Health Centers (FQHCs) to be charged more than the 340B ceiling price at the point of purchase. It also clarifies that arrangements where an FQHC pays more up front and later receives rebates, reimbursements, or other reconciliation that bring the net price down to the 340B ceiling are not permitted. The rule change takes effect on enactment and applies to drugs purchased on or after enactment; it also applies to determinations about whether existing agreements comply with 340B requirements beginning on enactment.
Official title: To amend title III of the Public Health Service Act to ensure that Federally-qualified health centers are not required to pay more than the 340B ceiling price for covered outpatient drugs at the time of purchase.
Introduced February 5, 2026 by John Bergman · Last progress February 5, 2026